m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics as proximal driver in m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
How does N6-methyladenosine (m6A) RNA modification alter alpha-synuclein mRNA stability and protein aggregation kinetics in substantia nigra dopaminergic neurons, and can pharmacological manipulation of m6A writers/erasers reduce Lewy body formation in PD model systems?
m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics should produce a measurable proximal phenotype before late disease pathology. The decisive test is dopaminergic-neuron perturbation of m6A writers/erasers/readers with RNA stability, translation, and Lewy-body-like aggregation assays.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["METTL3/METTL14 Complex m6A Writer Activity on SNCA Transcripts"]
B["YTHDF1/DF2/DF3 Recognition m6A Modification at 3UTR and CDS"]
C["SNCA mRNA Stability Modulation Translation Efficiency Altered"]
D["pSer129-SNCA Aggregation Hyperphosphorylated Alpha-Synuclein Accumulation"]
E["Lewy Body Formation Intraneuronal Protein Aggregation"]
F["PD Neurodegeneration Dopaminergic Neuron Loss in Substantia Nigra"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#4a148c,stroke:#ce93d8,color:#ce93d8
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations5 with PMID5 mediumValidation: 0%6 supporting / 1 opposing
✓For(6)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
3
MECH 4CLIN 0GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Neuronal identity defines α-synuclein and tau toxi…
global m6A manipulation can create broad toxicity and indirect proteostasis effects
Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theorist position for analysis b7f886d9-da3f-4e0d-a8a8-9c262e268796: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
Source basis: Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease (Molecular Psychiatry, 2024, DOI 10.1038/s41380-024-02574-w). The stored gap context says: Multi-omics analysis implicated m6A modification in PD risk but the causal downstream mechanism on alpha-synuclein biology was not established.
Primary hypothesis: m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics is
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic critique for analysis b7f886d9-da3f-4e0d-a8a8-9c262e268796: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: global m6A manipulation can create broad toxicity and indirect proteostasis effects.
The debate should re
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain expert assessment for analysis b7f886d9-da3f-4e0d-a8a8-9c262e268796: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational bio
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics as proximal driver in m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra", "description": "m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics should produce a measurable proximal phenotype before late disease pathology. The decisive test is dopaminergic-neuron perturbation of m6A writers/erasers/readers with RNA stability, translation, and Lewy-body-like aggregation assays.", "target_gene": "m6A",
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.